This publication is based on the proceedings of a meeting of European HIV experts convened in Windsor, UK, in March 2009. The meeting reviewed data in four key topics affecting the late presentation of HIV patients in Europe: the definition and epidemiology of late presentation, its medical and societal consequences, the need for earlier HIV testing and strategies for management of late- presenting patients. Each topic is discussed in detail here. A concluding article presents recommendations in each topic that were developed at the meeting to address the continuing challenge represented by late presentation for HIV treatment.
References
1.
ClumeckN., PozniakA., RaffF.European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.HIV Med2008; 9: 65–71.
2.
Panel on antiretroviral guidelines for adults and adolescents: guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. (Updated 01 December 2009. Accessed 12 January 2010.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
3.
GazzardB.G.British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.HIV Med2008; 9: 563–608.
4.
HammerS.M., EronJ.J.Jr., ReissP.Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel.JAMA2008; 300: 555–570.
5.
AdlerA., Mounier-JackS., CokerR.J.Late diagnosis of HIV in Europe: definitional and public health challenges.AIDS Care2009; 21: 284–293.
6.
GirardiE., SabinC.A., MonforteA.D.Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing.J Acquir Immune Defic Syndr2007; 46 Suppl 1: S3–S8.
7.
SandersG.D., BayoumiA.M., SundaramV.Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.N Engl J Med2005; 352: 570–585.
8.
JohnsonM., SabinC., GirardiE.Definition and epidemiology of late presentation in Europe.Antivir Ther2010; 15 Suppl 1: 3–8.
9.
MorenoS., MocroftA., d'Arminio MonforteA.Medical and societal consequences of late presentation.Antivir Ther2010; 15 Suppl 1: 9–15.
10.
EggerM., MayM., CheneG.Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.Lancet2002; 360: 119–129.
11.
YazdanpanahY., LangeJ., GerstoftJ., CairnsG.Early testing for HIV – how do we prevent late presentation?Antivir Ther2010; 15 Suppl 1: 17–24.
12.
Mounier-JackS., NielsenS., CokerR.J.HIV testing strategies across European countries.HIV Med2008; 9 Suppl 2: 13–19.
13.
RockstrohJ.K., GatellJ., LandmanR., AntinoriA.Management of late-presenting patients with HIV infection.Antivir Ther2010; 15 Suppl 1: 25–30.
14.
AntinoriA., JohnsonM., MorenoS., YazdanpanahY., RockstrohJ.K.Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation.Antivir Ther2010; 15 Suppl 1: 31–35.
15.
HIV in Europe.HIV in Europe website (Updated 12 January 2010. Accessed 12 January 2010.) Available from http://www.hiveurope.eu/.
